William L. Bigbee and coauthors suggest a panel of biomarkers—PRL (prolactin), TTR (transthyretin), THBS1 (thrombospondin 1), SELE (selectin E), MIF (macrophage migration inhibitory factor), PLAT (plasminogen activator, tissue type), EGFR, ERBB2 (erb-b2 receptor tyrosine kinase 2), CYFRA 21-1, and serum APBA (2-dehydropantoate 2-reductase)for early lung cancer diagnosis with 77.1% sensitivity and 76.2% specificity [80]. This evidence concerns the gene PRL and lung carcinoma.